Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells

Uchida,Daisuke; Kuribayashi,Nobuyuki; Kinouchi,Makoto; Sawatani,Yuta; Shimura,Michiko; Mori,Toshimitsu; Hasegawa,Tomonori; Miyamoto,Youji; Kawamata,Hitoshi

doi:10.3892/or.2018.6400

Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells

Authors:
- Daisuke Uchida
- Nobuyuki Kuribayashi
- Makoto Kinouchi
- Yuta Sawatani
- Michiko Shimura
- Toshimitsu Mori
- Tomonori Hasegawa
- Youji Miyamoto
- Hitoshi Kawamata
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, Tochigi 321‑0293, Japan, Department of Oral Surgery, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770‑8504, Japan
Published online on: April 25, 2018 https://doi.org/10.3892/or.2018.6400
Pages: 303-308

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We have previously demonstrated that the stromal cell‑derived factor (SDF‑1)/CXCR4 system is involved in the metastasis of head and neck cancer. Additionally, it has been revealed that the blockade of CXCR4 by subcutaneous daily injection with AMD3100, a CXCR4 antagonist, may be effective in preventing metastasis in CXCR4‑related head and neck cancer. Recent investigations have suggested that AMD070, a novel orally bioavailable inhibitor of CXCR4, may be minimally invasive compared with AMD3100. In the present study, we examined the effect of AMD070 on metastasis induced by the SDF‑1/CXCR4 axis in B88‑SDF‑1 oral cancer cells, which express high levels of SDF‑1 and CXCR4. Although treatment with AMD070 did not affect the anchorage‑dependent growth of B88‑SDF‑1 cells, it significantly suppressed the anchorage‑independent growth. Moreover, the SDF‑1/CXCR4‑dependent migration and invasion of B88‑SDF‑1 cells was significantly inhibited following treatment with AMD070. Subsequently, we performed an experimental therapy using AMD070 to prevent the distant metastasis of B88‑SDF‑1 cells in vivo. Daily oral administration of AMD070 significantly inhibited the lung metastasis of B88‑SDF‑1 cells in nude mice. These results indicated that AMD070 could be useful as a novel orally bioavailable inhibitor of oral cancer metastasis.

View Figures

View References

1	Uchida D, Begum NM, Almofti A, Nakashiro K, Kawamata H, Tateishi Y, Hamakawa H, Yoshida H and Sato M: Possible role of stromal-cell-derived factor-1/CXCR4 signaling on lymph node metastasis of oral squamous cell carcinoma. Exp Cell Res. 290:289–302. 2003. View Article : Google Scholar : PubMed/NCBI
2	Uchida D, Begum NM, Tomizuka Y, Bando T, Almofti A, Yoshida H and Sato M: Acquisition of lymph node, but not distant metastatic potentials, by the overexpression of CXCR4 in human oral squamous cell carcinoma. Lab Invest. 84:1538–1546. 2004. View Article : Google Scholar : PubMed/NCBI
3	Almofti A, Uchida D, Begum NM, Tomizuka Y, Iga H, Yoshida H and Sato M: The clinicopathological significance of the expression of CXCR4 protein in oral squamous cell carcinoma. Int J Oncol. 25:65–71. 2004.PubMed/NCBI
4	Onoue T, Uchida D, Begum NM, Tomizuka Y, Yoshida H and Sato M: Epithelial-mesenchymal transition induced by the stromal cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells. Int J Oncol. 29:1133–1138. 2006.PubMed/NCBI
5	Uchida D, Onoue T, Tomizuka Y, Begum NM, Miwa Y, Yoshida H and Sato M: Involvement of an autocrine stromal cell derived factor-1/CXCR4 system on the distant metastasis of human oral squamous cell carcinoma. Mol Cancer Res. 5:685–694. 2007. View Article : Google Scholar : PubMed/NCBI
6	Uchida D, Kuribayashi N, Kinouchi M, Ohe G, Tamatani T, Nagai H and Miyamoto Y: Expression and function of CXCR4 in human salivary gland cancers. Clin Exp Metastasis. 30:133–142. 2013. View Article : Google Scholar : PubMed/NCBI
7	Uchida D, Onoue T, Kuribayashi N, Tomizuka Y, Tamatani T, Nagai H and Miyamoto Y: Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases. Eur J Cancer. 47:452–459. 2011. View Article : Google Scholar : PubMed/NCBI
8	De Clercq E: The bicyclam AMD3100 story. Nat Rev Drug Discov. 2:581–587. 2003. View Article : Google Scholar : PubMed/NCBI
9	Genzyme: Investigator's Brochure for Plerixafor Injection (AMD3100, Mozobil). 1–142. 2012.
10	Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature. 410:50–56. 2001. View Article : Google Scholar : PubMed/NCBI
11	Scotton CJ, Wilson JL, Milliken D, Stamp G and Balkwill FR: Epithelial cancer cell migration: A role for chemokine receptors? Cancer Res. 61:4961–4965. 2001.PubMed/NCBI
12	Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS and McCauley LK: Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 62:1832–1837. 2002.PubMed/NCBI
13	Schrader AJ, Lechner O, Templin M, Dittmar KE, Machtens S, Mengel M, Probst-Kepper M, Franzke A, Wollensak T, Gatzlaff P, et al: CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer. 86:1250–1256. 2002. View Article : Google Scholar : PubMed/NCBI
14	Zhou Y, Larsen PH, Hao C and Yong VW: CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem. 277:49481–49487. 2002. View Article : Google Scholar : PubMed/NCBI
15	Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, Sattler M, Johnson BE and Salgia R: Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res. 62:6304–6311. 2002.PubMed/NCBI
16	Cabioglu N, Summy J, Miller C, Parikh NU, Sahin AA, Tuzlali S, Pumiglia K, Gallick GE and Price JE: CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res. 65:6493–6497. 2005. View Article : Google Scholar : PubMed/NCBI
17	Hartmann TN, Burger JA, Glodek A, Fujii N and Burger M: CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene. 24:4462–4471. 2005. View Article : Google Scholar : PubMed/NCBI
18	Yasumoto K, Koizumi K, Kawashima A, Saitoh Y, Arita Y, Shinohara K, Minami T, Nakayama T, Sakurai H, Takahashi Y, et al: Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res. 66:2181–2187. 2006. View Article : Google Scholar : PubMed/NCBI
19	Marchesi F, Monti P, Leone BE, Zerbi A, Vecchi A, Piemonti L, Mantovani A and Allavena P: Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res. 64:8420–8427. 2004. View Article : Google Scholar : PubMed/NCBI
20	Stone ND, Dunaway SB, Flexner C, Tierney C, Calandra GB, Becker S, Cao YJ, Wiggins IP, Conley J, MacFarland RT, et al: Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother. 51:2351–2358. 2007. View Article : Google Scholar : PubMed/NCBI
21	Mosi RM, Anastassova V, Cox J, Darkes MC, Idzan SR, Labrecque J, Lau G, Nelson KL, Patel K, Santucci Z, et al: The molecular pharmacology of AMD11070: An orally bioavailable CXCR4 HIV entry inhibitor. Biochem Pharmacol. 83:472–479. 2012. View Article : Google Scholar : PubMed/NCBI
22	Parameswaran R, Yu M, Lim M, Groffen J and Heisterkamp N: Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia. 25:1314–1323. 2011. View Article : Google Scholar : PubMed/NCBI
23	Morimoto M, Matsuo Y, Koide S, Tsuboi K, Shamoto T, Sato T, Saito K, Takahashi H and Takeyama H: Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: Effect of CXCR4 antagonists. BMC Cancer. 16:3052016. View Article : Google Scholar : PubMed/NCBI
24	Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J and Springer TA: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 382:829–833. 1996. View Article : Google Scholar : PubMed/NCBI
25	Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H and Kishimoto T: Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 382:635–638. 1996. View Article : Google Scholar : PubMed/NCBI
26	Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, et al: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature. 382:833–835. 1996. View Article : Google Scholar : PubMed/NCBI
27	Aiuti A, Webb IJ, Bleul C, Springer T and Gutierrez-Ramos JC: The chemokine SDF-1 is a chemoattractant for human CD34⁺ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34⁺ progenitors to peripheral blood. J Exp Med. 185:111–120. 1997. View Article : Google Scholar : PubMed/NCBI
28	Hwang JH, Hwang JH, Chung HK, Kim DW, Hwang ES, Suh JM, Kim H, You KH, Kwon OY, Ro HK, et al: CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells. J Clin Endocrinol Metab. 88:408–416. 2003. View Article : Google Scholar : PubMed/NCBI
29	Zhang L, Yeger H, Das B, Irwin MS and Baruchel S: Tissue microenvironment modulates CXCR4 expression and tumor metastasis in neuroblastoma. Neoplasia. 9:36–46. 2007. View Article : Google Scholar : PubMed/NCBI
30	Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G and Castello G: Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res. 11:1835–1841. 2005. View Article : Google Scholar : PubMed/NCBI
31	Scala S: Molecular Pathways: Targeting the CXCR4-CXCL12 axis - untapped potential in the tumor microenvironment. Clin Cancer Res. 21:4278–4285. 2015. View Article : Google Scholar : PubMed/NCBI
32	Debnath B, Xu S, Grande F, Garofalo A and Neamati N: Small molecule inhibitors of CXCR4. Theranostics. 3:47–75. 2013. View Article : Google Scholar : PubMed/NCBI
33	Skerlj RT, Bridger GJ, Kaller A, McEachern EJ, Crawford JB, Zhou Y, Atsma B, Langille J, Nan S, Veale D, et al: Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem. 53:3376–3388. 2010. View Article : Google Scholar : PubMed/NCBI
34	O'Boyle G, Swidenbank I, Marshall H, Barker CE, Armstrong J, White SA, Fricker SP, Plummer R, Wright M and Lovat PE: Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070. Br J Cancer. 108:1634–1640. 2013. View Article : Google Scholar : PubMed/NCBI
35	Tisdale MJ: Biology of cachexia. J Natl Cancer Inst. 89:1763–1773. 1997. View Article : Google Scholar : PubMed/NCBI
36	Van Hout A, D'huys T, Oeyen M, Schols D and Van Loy T: Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors. PLoS One. 12:e01760572017. View Article : Google Scholar : PubMed/NCBI